Suppressing unwanted humoral immune responses without compromising the host’s ability to respond to foreign pathogens is a primary goal for therapies aimed at ameliorating harmful autoantibody production. Global suppression of the immune system via lymphocyte depletion and/or immunosuppressive drugs can have off-target effects, a limitation to conventional therapies. In this issue of the
Craig P. Chappell, Edward A. Clark
Multiple cellular and molecular targets for modulating Ag-specific B cell responses.